Why does this broker say to sell Cochlear (ASX:COH) shares in 2022?

Can Cochlear defy this broker's odds?

| More on:
a young boy in profile shows the cochlear implant devide fitted to his ear and attached to the side of his head to help him to process sounds.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Cochlear share price has held its gains over the last 12 months
  • One broker is downbeat on the outlook for the company's shares for 2022
  • But not all brokers are as pessimistic. 

Shares in hearing technology player Cochlear Limited (ASX: COH) are edging ahead today and, at the time of writing, are 0.46% in the green at $215.44 apiece.

Unlike many of its S&P ASX 200 Index (ASX: XJO) peers, the Cochlear share price has held gains across the last 12 months and into the new year. This year to date, Cochlear shares are flat whereas, in the previous year, they climbed 8%.

Despite their positive momentum on the chart, one broker isn't so rosy on the outlook for Cochlear shares in 2022, urging its clients to either sell or downsize their positions.

TradingView Chart

Why does this broker say sell Cochlear shares?

Analysts at RBC Capital Markets are cautious about the hearing specialist given the company's slowing sales growth and questionable valuation.

The broker initiated coverage on the Cochlear share price and anticipates it to underperform in 2022. It notes its revenue growth has fallen off, alongside other growth metrics in recent times.

This means Cochlear no longer commands the valuation premium it once did, seeing as cash flows into the future don't appear to be as large as first thought.

Not only that, but the seniors market for hearing technology is becoming more saturated, meaning Cochlear runs the risk of losing market share to competitors in that space, RBC says.

RBC values the company at a significantly discounted $149 per share, suggesting a downside potential of 31% at the time of writing.

It's not all downbeat – one broker upgrades to neutral

Meanwhile, analysts at fellow broker Morgan Stanley note that Cochlear's annual guidance looks to be a bit soft, even amid the weakening sales outlook.

The broker reckons Cochlear will offset the tightening sales through service and upgrade revenue which it feels will continue to hold strong in FY22.

For reference, Cochlear grew services revenue by 21% year on year and acoustics sales were 40% higher from the same time last year.

Given its healthy assessment on the stock, Morgan Stanley upgraded its rating to equal-weight from underweight to reflect the more positive sentiment.

It values Cochlear at $208 per share after raising its price target by 16% in a recent note.

The consensus price target for Cochlear is $221 per share, according to Bloomberg Intelligence, meaning the sentiment is still bullish from the 21 analysts covering the stock.

In fact, 42.1% have it as a buy, another 42.1% have it as a hold right now, with the remaining 15.8% advocating to sell Cochlear shares.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Young man with a laptop in hand watching stocks and trends on a digital chart.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A female sharemarket analyst with red hair and wearing glasses looks at her computer screen watching share price movements.
Broker Notes

Up 34% this year, can Challenger shares keep rising according to Macquarie?

The leading broker has released a new research note.

Read more »

Two parents and two children happily eat pizza in their kitchen.
Broker Notes

Morgans reveals 4 ASX All Ords shares to buy now — and 2 may surprise you

The top broker has revealed a buy rating on four ASX All Ords shares from different market sectors.

Read more »

Five happy miners standing next to each other representing ASX coal mining shares which some brokers say could pay big dividends this year
Broker Notes

Macquarie predicts 63% upside for this ASX 200 mining stock

Which ASX 200 stock is it?

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Broker Notes

These ASX 200 shares could rise 15% to 30%

Let's see what brokers are saying about these buy-rated top stocks.

Read more »

A female stockbroker reviews share price performance in her office with the city shown in the background through her windows
Broker Notes

JP Morgan initiates coverage of Guzman Y Gomez shares. What's its price target?

Does the broker expect Guzman Y Gomez to outperform?

Read more »

Happy man working on his laptop.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Worker on a laptop at an oil and gas pipeline.
Energy Shares

Boss Energy shares have surged 93% since April. Here's what Macquarie expects now

Boss Energy shares remain a favourite for ASX short sellers. Are they in a for a payday or headed for…

Read more »